Limited-dose Daclizumab versus Basiliximab: A comparison of cost and efficacy in preventing acute rejection

Transplantation Proceedings

Volumn 37, Issue 2, 2005, Pages 899-902

  Pham, K ^a   Kraft, K ^a   Thielke, J ^a   Oberholzer, J ^a   Sankary, H ^a   Testa, G ^a   Benedetti, E ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; DACLIZUMAB;

ACUTE GRAFT REJECTION; ADULT; AGE DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; SIDE EFFECT; STANDARDIZATION; TREATMENT OUTCOME;

EID: 17844386363     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.12.079     Document Type: Conference Paper

References (10)

1. G. Niemeyer, K. Martina, S. Light Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients Am J Transplant 2 2002 454
2. T.A. Waldmann, J. O'Shea The use of antibodies against the IL-2 receptor in transplantation Curr Opin Immunol 10 1998 507
3. D. Adu, P. Cockwell, N.J. Ives Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomized trials BMJ 326 2003 789
4. A. Beniaminovitz, S. Itescu, K. Lietz Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody N Engl J Med 342 2000 613
5. F. Vincenti Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation Transplant Proc 31 1999 2206
6. F. Vincenti, B. Pace, J. Birnbaum Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation Am J Transplant 3 2002 50
7. F. Vincenti, B. Nashan, S. Light Daclizumab: outcome of phase III trials and mechanism of action Transplant Proc 30 1998 215
8. B. Philosophe, A.M. Wiland, D.L. Mann Prospective randomized study comparing OKT3 and a truncated daclizumab regimen as induction for marginal kidneys at high-risk for delayed graft function Am J Transplant S3 2002 239
9. N. Ahsan, M. Holman, M.V. Jarowenko Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation Am J Transplant 2 2002 568
10. R.J. Stratta, R.R. Alloway, E. Hodge A multicenter, open-label comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis Clin Transplant 16 2002 60